AC Immune SA
This article was originally published in Start Up
Swiss-based AC Immune SA is using both an immunological and a small molecule approach to tackling Alzheimer's disease. It hopes that both techniques may lead to compounds that may, by re-balancing the equilibrium between mutant and harmless forms of the protein amyloid beta, halt and perhaps even reverse the progression of the disease.
You may also be interested in...
Four start-ups previously profiled in START-UP – CoMentis, EnVivo Pharmaceuticals, Avid Radiopharmaceuticals and AC Immune SA – show how some biotechs have successfully ridden through the rough patches any company brave enough to tackle Alzheimer’s disease will likely face.
The crux of the discovery platform of Reata is an assay that reveals, basically in real time, the effect that small molecules are having on the folding behavior of proteins. Reata aims to harness this capability to identify compounds that beneficially influence proteins known to underlie diseases that are prone to misfolding in specific ways. In the case of Alzheimer's disease, Reata is looking at amyloid-beta , the principal component in the plaques found in the brains of AD patients, and at tau, which forms protein inclusions, or tangles, involved in a number of neurodegenerative diseases.
Senexis Ltd. spun-out of the University of Manchester Institute of Science and Technology to develop novel therapeutics and diagnostics for currently incurable aging-related disorders such as Alzheimer's disease, Parkinson's disease and type 2 diabetes. In addition to being more prevalent in the older population, these diseases also share a similar underlying etiology; they are all associated with amyloidosis.